论文部分内容阅读
目的探讨生长激素(GH)联合促性腺激素释放激素类似物(GnRHa)治疗基础身高较低的特发性中枢性性早熟(ICPP)的临床疗效。方法收集11例就诊时身高位于同年龄、性别身高的第50百分位点及以下(排除矮小症)确诊为ICPP女童,予GH+GnRHa联合治疗1年,对治疗前后的类胰岛素样生长因子(IGF1)、生长速度(GV)及预测成年身高(PAH),按骨龄的身高标准差分值(HtSDSBA)和骨龄(BA)进行比较。结果联合治疗后IGF1、GV、PAH及HtSDSBA均较治疗前有显著增加。结论 GH+GnRHa联合治疗能明显改善基础身高较低的ICPP女童的PAH。
Objective To investigate the clinical effects of growth hormone (GH) combined with gonadotropin-releasing hormone analogues (GnRHa) on the treatment of idiopathic central precocious puberty (ICPP) with lower height. Methods Eleven patients were diagnosed ICPP female whose height was at the same age and sex height at the time of diagnosis and the following (rule out short stature) were collected and treated with GH + GnRHa for 1 year. Before and after treatment, insulin-like growth factor (IGF1), growth rate (GV) and predicted adult height (PAH) were compared. The standard deviation of height at bone age (HtSDSBA) and bone age (BA) were compared. Results IGF1, GV, PAH and HtSDSBA increased significantly after treatment. Conclusions GH + GnRHa combination therapy can significantly improve PAH in ICPP girls with basic height.